Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Reduce-MFA: Antifibrotic Therapy in TAVI Patients
NCT05230901Phase 3Recruiting
- Sponsor
- Universitätsmedizin Göttingen
- Start
- Feb 2022
- Primary completion
- Jun 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of spironolactone, dihydralazine in myocardial fibrosis, sponsored by Universitätsmedizin Göttingen. Started Feb 2022; status: recruiting.
02
Drugs
spironolactonedihydralazine
03
Conditions
myocardial fibrosis
Beyond the preview
Go deeper on NCT05230901.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05230901.